Open AccessAssessing the Feasibility of Replacing Standard-Dose Bacillus Calmette–Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis
Author(s) -
Cheng Wu,
Xingqin Zhou,
Chunqing Miao,
Jianzhong Zhang,
Qingsheng Tang,
Xiumei Chang,
Haodong Ni
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000464432
Subject(s) - medicine , bladder cancer , bcg vaccine , immunotherapy , urology , oncology , epirubicin , odds ratio , confidence interval , cancer , surgery , tuberculosis , pathology , breast cancer
Bacillus Calmette-Guérin (BCG) immunotherapy plays a key role in patients with bladder cancer. The shortage of intravesical BCG has motivated researchers to seek alternatives with equivalent efficacy If other alternative intravesical agents have equivalent efficacy compared to BCG, then it may be feasible to replace standard BCG with alternative options.